


# ASCO DATA REVIEW 2025

July 17, 2025



**SERENA-6:** Switching to camizestrant with continuation of CDK4/6i guided by ctDNA improves PFS and should be a new treatment strategy... not yet FDA approved...

**DESTINY-Breast09:** The combination of T-DXd plus pertuzumab has the potential to be a new first-line standard of care for patients with HER2+ mBC... not yet approved... more to come...

**DESTINY-Breast06:** T-DXd is an effective treatment strategy regardless of mutational status for HR+, HER2-low or -ultralow mBC after prior endocrine-based therapy... FDA approved since January 2025

**Treatment rechallenge after trastuzumab-deruxtecan related ILD:** Steroid use results in fast radiographic ILD improvement and rechallenge with T-DXd after grade 1 ILD is possible with limited, low-grade recurrence of ILD

**ASCENT-03:** Positive topline results from the Phase 3 ASCENT-03 study of sacituzumab govitecan-hziy suggest benefit for 1L metastatic TNBC patients... not yet approved in earlier line setting, more to come...

**ASCENT-04:** The combination of sacituzumab govitecan-hziy plus pembrolizumab is a potential new treatment option for select patients previously untreated with PD-L1 positive locally advanced or metastatic TNBC... not yet approved... more to come...

**VERITAC-2:** Vepdegestrant, benefitted patients with previously treated ESR1-mutant ER+, HER2- mBC: mPFS 5.0 mos. EMERALD, elacestrant vs fulvestrant in ESR1m, ER+/HER2- mBC ≤1 prior chemo: mPFS 3.8 mos HR 0.55

**INAVO120:** Adding inavolisib to palbociclib and fulvestrant is a new standard of care that can benefit select patients with PIK3CA-mutated, HR+ve, HER2-ve advanced breast cancer... the hyperglycemia with this regimen is a huge clinical problem - particularly knowing that they excluded patients with diabetes

**CompassHER2 pCR:** Clinicopathologic factors and HER2DX scores can be utilized to identify patients who have no residual disease after THP and surgery, and can forgo further chemotherapy

**ATOMIC:** Atezolizumab plus mFOLFOX6 could be considered a new standard adjuvant treatment for patients with stage III deficient DNA mismatch repair colon cancer... not yet FDA approved

**MATTERHORN:** Perioperative durvalumab with chemotherapy (FLOT) could be a new standard treatment for patients with localized gastric and GEJ adenocarcinoma... not yet FDA approved

**DESTINY-Gastric04:** Trastuzumab deruxtecan should be considered as a standard second-line therapy for patients with metastatic HER2-positive gastric cancer... FDA approved since January 2021

**BREAKWATER:** Encorafenib plus cetuximab with mFOLFOX6 is could be a new standard first-line therapy for patients with BRAF V600E-mutant metastatic colorectal cancer... FDA approval since December 2024

**PANOVA-3:** Tumor Treating Fields (radiation) with gemcitabine and nab-paclitaxel is a potential new standard paradigm for unresectable locally advanced pancreatic adenocarcinoma... not yet FDA approved

**AMPLITUDE:** Niraparib and abiraterone acetate plus prednisone could become a new standard treatment for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair genes... not yet FDA approved

**NIVOPOSTOP:** Post-operative nivolumab added to SOC cisplatin-RT benefited patients for resected high-risk LA-SCCH and could be proposed as a new standard treatment... not yet FDA approved

**KEYNOTE-689:** Neoadjuvant pembrolizumab followed by surgery and adjuvant pembrolizumab concurrent with and after postoperative (chemo)radiotherapy could be a new standard of care in the treatment of patients with resectable locally advanced head and neck cancer... FDA approved since June 2025

**VERIFY:** Rusefertide plus phlebotomy ± cytoreductive therapy improved patient outcomes and should be considered as a new treatment option for patients with PV... not yet FDA approved

**TROPION-Lung02:** Dato-DXd + pembrolizumab ± platinum chemotherapy showed encouraging activity in patients with NSCLC in 1L and 2L setting. More to come... TROPION-Lung07 (1L mNSCLC, PD-L1 <50%) and TROPION-Lung08 (1L mNSCLC, PD-L1 ≥50%)

**DELLPHI-304:** Phase 3 study confirmed that 2L tarlatamab improved medical survival compared to chemo SOC... accelerated FDA approval granted in May 2024

**IMforte:** Lurbinectedin + 1L chemo+ICI improved survival in ES-SCLC in patient without progression after chemo... not yet FDA approved

**TUXEDO-3:** HER3-DXd showed activity to benefit patients with active brain mets or leptomeningeal disease... not yet FDA approved

**ROSELLA:** Adding Relacorilant to nab-paclitaxel improved mOS in patients with platinum-resistant ovarian cancer... not yet FDA-approved... PDUFA date Dec 30, 2025

## Program Chairs

**EDITH A. PEREZ, MD** - Breast Cancer  
Cornerstone Specialty Network

**SUJITH R. KALMADI, MD** - GU/GI Cancer  
Ironwood Cancer and Research Centers, Phoenix, AZ

**ERIC S. SCHAEFER, MD** - Other notable studies  
Highlands Oncology Group, Fayetteville, AR

**cornerstone**  
specialty network™